# 2025

(Pharmacy)




# GNIPST BULLETIN

Volume-3, Issue- 5

GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India

# Table of Contents



# MESSAGE FROM HONORABLE DIRECTOR



As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings and warm wishes to all our students, faculty, staff, alumni, and well-wishers on the joyful occasion of Children's Day.

Children's Day celebrates the spirit of childhood — a time filled with curiosity, creativity, innocence, and limitless possibilities. It reminds us that every child is a reservoir of potential, deserving of love, guidance, education, and opportunities to grow. At GNIPST, we firmly believe that Anurturing young minds with knowledge, compassion, and values lays the foundation for a brighter, stronger, and more enlightened future.

As educators and mentors, it is our responsibility to encourage students to dream fearlessly, learn wholeheartedly, and develop the confidence to shape their own destinies. Let us work together to create an environment that fosters curiosity, innovation, and holistic development, ensuring that every child feels valued, empowered, and inspired.

On this special day, may we reaffirm our commitment to building a nurturing academic community where learning becomes a joyous journey and every child's uniqueness is celebrated.

Wishing everyone a Happy Children's Day!

May the day bring joy, hope, and inspiration to all.

*Prof. (Dr.) Abhijit Sengupta*

# MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and best wishes to our students, faculty, staff, alumni, and valued partners on the joyful occasion of Children's Day. This special day celebrates childhood — a phase filled with innocence, curiosity, creativity, and immense potential. It reminds us of the importance of nurturing young minds with care, knowledge, and opportunities so they may grow into confident, responsible, and compassionate individuals.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we believe that education is the most powerful gift we can offer to our children — a light that dispels ignorance, inspires discovery, and shapes the leaders of tomorrow. Since our inception in 2005, GNIPST has continued to evolve as a distinguished centre of pharmaceutical education, recognized by the Pharmacy Council of India (PCI) and celebrated as the first institution in the region to achieve both NAAC and NBA accreditations. Our recent accomplishment of securing the 85th rank in NIRF 2025 reflects our unwavering commitment to quality, growth, and academic excellence.

On this meaningful day, let us reaffirm our responsibility to guide, inspire, and empower our students. Let us foster an environment that celebrates curiosity, encourages innovation, and nurtures the holistic development of every child. Together, we can ensure that each young learner feels valued, supported, and motivated to reach new heights.

Wishing everyone a Happy Children's Day!

May this day bring joy, hope, and inspiration to every child and to all who play a role in shaping their future.

*Prof. (Dr.) Lopamudra Datta*

# RECENT RESEARCHES

**MERS-CoV virus isolate added to the WHO BioHub System, enabling further research and pandemic preparedness**

MORE INFO

www.who.int/

countermAn isolate of Middle East respiratory syndrome coronavirus (MERS-CoV), one of three high-impact coronaviruses with pandemic potential to have emerged in recent years, has been added to the WHO BioHub System. Through the BioHub, countries can voluntarily share and request biological materials with epidemic or pandemic potential. This initiative, set up by the Director-General of WHO during the COVID-19 pandemic, directly supports pathogen characterization and research, surveillance and risk assessments, and in the future will contribute to the development of medical easures such as diagnostics, vaccines, and therapeutics by enabling rapid access to verified biological materials and data essential for advancing research, validation, and product development. MERS-CoV is a zoonotic virus and can be transmitted between dromedary camels and humans. Infection in people may lead to acute respiratory disease and even death, with a fatal outcome in 37% of cases reported to date. There are currently no licensed vaccines or therapeutics against MERS.

**Strengthening global public health through traditional medicine: 3rd World Congress on Traditional, Complementary and Integrative Medicine**

MORE INFO

www.who.int/

The 3rd World Congress on Traditional, Complementary and Integrative Medicine (TCIM) took place on 15–18 October 2025 in Rio de Janeiro, Brazil. It marked the 20th International Congress on TCIM Research and the 17th European Congress on Integrative Medicine and aligned with the release of the WHO Global Traditional Medicine Strategy 2025–2034, adopted at the Seventy-eighth World Health Assembly in May 2025. The event brought together researchers from across the globe to discuss innovative solutions for strengthening global public health through TCIM.

**Recommendations announced for influenza vaccine composition for the 2026 southern hemisphere influenza season**

MORE INFO

www.who.int/

The World Health Organization (WHO) convened the Interregional Training Workshop on Ensuring the Quality and Safety of Traditional, Complementary and Integrative (TCI) Medicine Products from 22–24 October 2025 in Macao SAR, China. The workshop was organized as part of WHO's ongoing efforts to strengthen regulatory systems and promote safe integration of traditional, complementary and integrative medicine (TCIM) into national health systems. The training brought together more than 40 participants from 18 countries and two Special Administrative Regions (Angola, Brazil, Cabo Verde, China, Egypt, India, Indonesia, Iraq, Lao People's Democratic Republic, Malaysia, Mozambique, Nepal, Pakistan, Poland, the Republic of Korea, Thailand, Timor-Leste, and Viet Nam, as well as Hong Kong SAR China and Macao SAR China), representing the six WHO regions. Participants included government regulators, technical experts, researchers, and representatives from WHO Collaborating Centres, who shared national experiences and explored practical approaches to quality assurance, safety monitoring, and evidence generation for TCIM products.

# NEW DRUG APPROVALS

October, 2025

GNIPST BULLETIN 2025

## Eydenzelt (aflibercept-boav) Injection

- Date of Approval: October 2, 2025
- Company: Celltrion USA, Inc.
- Treatment for: Macular Degeneration,

## Lasix ONYU (furosemide) Injection

- Date of Approval: October 7, 2025
- Company: SQ Innovation, Inc.
- Treatment for: Edema

## Ferabright (ferumoxytol) Injection

- Date of Approval: October 16, 2025
- Company: Azurity Pharmaceuticals, Inc.
- Treatment for: Diagnosis and Investigation

## Epioxa (riboflavin 5'-phosphate) Ophthalmic Solution

- Date of Approval: October 17, 2025
- Company: Glaukos Corporation

## Contepo (fosfomycin) for Injection

- Date of Approval: October 22, 2025
- Company: Meitheal Pharmaceuticals, Inc.
- Treatment for: Urinary Tract Infection

## Lynkuet (elinzanetant) Capsules

- Date of Approval: October 24, 2025
- Company: Bayer
- Treatment for: Hot Flashes, Menopause

## Jascayd (nerandomilast) Tablets

- Date of Approval: October 7, 2025
- Company: Boehringer Ingelheim Pharmaceuticals, Inc.
- Treatment for: Idiopathic Pulmonary Fibrosis

MORE INFO https://www.drugs.com/newdrugs.html.

# CLINICAL TRIAL NEWS



## 01. Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease

October 1, 2025 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer's disease. Fast Track Designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and fill an unmet medical need.

## 02. Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases

IOctober 6, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in patients with three immune-mediated inflammatory diseases:

- MK-7240-12 ( NCT06956235) studying patients with moderate to severe hidradenitis suppurativa(HS)

## 03. EBaxdrostat Met the Primary Endpoint in Bax24 Phase III Trial in Patients with Resistant Hypertension

7 October 2025 -- Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.

## 04. Novartis Ianalumab First Drug to Reduce Disease Activity and Patient Burden in Sjögren's Disease Phase III Trials

TOctober 29, 2025 – Novartis today presented new ianalumab data in Sjögren's disease, the second most prevalent rheumatic autoimmune disease[2], at a late-breaker presentation during the American College of Rheumatology Convergence congress[1].

## 05. Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Oct. 28, 2025-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced achievement of statistically significant improvement in liver function in patients treated with ADX-629, an investigational new drug candidate, and focused the RASP modulator product candidate pipeline on next-generation molecules ADX-248 and ADX-246.

## 06. Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes.

Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational medicine ofirnoflast (HT-6184) for the treatment of Myelodysplastic Syndromes (MDS) — a group of bone marrow disorders characterized by ineffective blood cell production and a risk of progression to acute myeloid leukemia (AML).

## 07. Gefurulimab Demonstrates Statistically Significant and Clinically Meaningful Improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) at Week 26 with Clinically Meaningful Improvement Seen as Early as Week One in Adults with gMG in PREVAIL Phase III Trial

30 October 2025 -- Positive results from the global PREVAIL Phase III trial showed that gefurulimab met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score compared to placebo in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia gravis (gMG) at week 26. PREVAIL also met all secondary endpoints, including change from baseline in Quantitative Myasthenia Gravis (QMG) total score at week four and week 26.[1]

These data were presented at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting in San Francisco, California.[1]

MORE INFORMATION

**https://www.drugs.com/clinical_trials_archive/january-2025.html**

# DISEASE OUTBREAK NEWS (DONS)

October, 2025



## Rift Valley fever- Mauritania and Senegal

5 November 2025

**Situation at a glance**

Between 20 September and 30 October 2025, a total of 404 confirmed human cases of Rift Valley fever (RVF), including 42 deaths, were reported by national health authorities in two West African countries: Mauritania and Senegal. RVF is a zoonotic disease, which mainly affects animals, but can also infect humans. The majority of human infections result from contact with the blood or organs of infected animals, but human infections have also resulted from the bites of infected mosquitoes. To date, no human-to-human transmission of RVF has been documented. While RVF often leads to severe illness in animals, its impact in humans varies, ranging from mild flu-like symptoms to severe hemorrhagic fever that can be fatal. RVF is endemic in both countries, where recurrent outbreaks have been previously reported in both livestock and humans. The risk of further spread remains high, especially with environmental conditions favorable to the proliferation of mosquitoes, periods of heavy rains and increased mosquito activity, as well as movements of livestock within country and towards Mali and Gambia for grazing and trade. The response to RVF outbreaks requires a One Health approach, based on enhanced collaboration between the human health, animal health and environmental sectors, in both countries and at the regional level. WHO, in collaboration with the World Organization for Animal Health (WOAH), and the Food and Agriculture Organization of the United Nations (FAO), currently assesses the overall risk as high at the national levels, moderate at the regional level and low at the global level.


MORE INFO https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON573

## Chikungunya virus disease- Global situation

3 October 2025

**Situation at a glance**

In 2025, a resurgence of chikungunya virus (CHIKV) disease was noted in a number of countries, including some that had not reported substantial case numbers in recent years. Between 1 January and 30 September 2025, a total of 445 271 suspected and confirmed CHIKV disease cases and 155 deaths were reported globally from 40 countries, including autochthonous and travel imported cases. Some WHO Regions are experiencing significant increases in case numbers compared to 2024, although others are currently reporting lower case numbers. This uneven distribution of cases across regions makes it challenging to characterize the situation as a global rise, however, given the ongoing outbreaks reported globally in 2025, the potential for further spread remains significant. CHIKV disease can be introduced into new areas by infected travelers and local transmission may be established if there is the presence of Aedes mosquito and a susceptible population. The risk is heightened by limited population immunity in previously unaffected areas, favorable environmental conditions for vector breeding, gaps in surveillance and diagnostic capacity, and increased human mobility and trade. Strengthening disease surveillance, enhancing vector surveillance and control, and improving public health preparedness are essential to mitigate the risk of further transmission.

MORE INFO https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON566

# CAMPUS NEWS



1. **Blanket Distribution Drive:** Students and faculty of GNIPST, in collaboration with the International Vedanta Society, conducted the Blanket Distribution Drive from 01st November to 02nd November 2025, spreading warmth and care across Bankura. The initiative reflected the institute's commitment to social responsibility and community welfare. True education was celebrated not just in classrooms, but in the heartfelt act of kindness shared with those in need.


**2. National Workshop:** The Gemini 2.5 Pro Access & AI Classroom session was held on 14th November 2025, from 2:00 PM to 4:00 PM at the GNIPST Auditorium. Organized by Guru Nanak Institute of Pharmaceutical Science and Technology in collaboration with Reliance Jio, the event highlighted transformative applications of AI in education and research. Participants enthusiastically explored next-generation tools, fostering innovation and digital learning excellence.

# Children's Day – Celebrating the Spirit of Childhood

Children's Day is celebrated on November 14th in India to honor Pandit Jawaharlal Nehru, who believed that children are the foundation of a successful society. to evolve into accountable and self-assured individuals. Educational institutions, community organizations, and familial units converge to venerate the innocence, joy, and latent potential inherent in every child. This occasion accentuates the necessity of safeguarding children's rights and ensuring their holistic well-being.

- Encourages quality education as the strongest tool for a better future.
- Encourages everyone to create a safe and happy place for kids. Enjoys kids' creativity and imagination.
- Inspires adults to respect, guide, and empower the younger generation.
- Children's Day reminds us that every child deserves love, care, dignity, and endless possibilities for a brighter tomorrow.

GNIPST GAME TIME





# FORMULATION ESCAPE ROOM

*Objective:*

Solve each formulation-related clue to "unlock" the next stage. A student escapes only after clearing all 4 stages.

*THE STORY*

You are working in a formulation lab. A critical parenteral product must be released by evening. But the system is locked!

**To unlock each chamber, you must solve formulation challenges.**

## STAGE 1 — Choose the Correct Excipients (Door 1)

*Question:*

You need to formulate an aqueous injection of a poorly water-soluble drug. Which combination of excipients will help?

**Options:**

A. Lactose + Starch
B. Propylene glycol + Ethanol
C. Talc + PVP K30
D. Magnesium stearate + SLS

## STAGE 2 — Select the Proper Sterilization Method (Door 2)

*Question:*

The drug is heat-sensitive. Which sterilization method should you select?

**Options:**

A. Autoclaving (121°C, steam)
B. Dry heat sterilization
C. Membrane filtration (0.22 µm)
D. Radiation sterilization

## STAGE 3 — Fix the Stability Issue (Door 3)

*Question:*

During stability testing, the formulation becomes discolored after light exposure. What is the most appropriate action?

**Options:**

A. Add lubricants
B. Use amber-colored vials
C. Increase viscosity
D. Add disintegrants

GNIPST BULLETIN 2025

# GNIPST GAME TIME



## FORMULATION ESCAPE ROOM

### STAGE 4 — Choose Suitable Packaging (Final Door)

*Question:*

This injection is prone to oxidation. Which packaging addition is BEST?

**Options:**

A. Nitrogen flushing
B. Cotton plug
C. PVC bottle
D. Aluminium foil blister

*Stay tuned for to the next edition for a shout out to fastest correct answers!*

**Submit your answer**

SCAN ME or CLICK HERE

## Celebrating the Achievers!

Volume -3, Issue -4

Sanchari Bhattacharya
Assistant Professor
Guru Nanak Institute of Pharmaceutical Science and Technology

# Editorial Board



GNIPST BULLETIN 2025

## COURSES OFFERED

### PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

### PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

### PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major Recruiters

Cipla, Cognizant, wipro, IQVIA, MACLEODS, ZIFO RnD SOLUTIONS, Nestlé, TRIMPLIN, FRESENIUS KABI, tcs

Latest news

www.gnipst.ac.in

www.facebook.com

www.instagram.com

www.linkedin.com

www.youtube.com

api.whatsapp.com